Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.
about
Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessImprovement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trialComparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institutePirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.A new method for repeated drug infusion into the femoral artery of mice.Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft.Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis.Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?The relation of tumour necrosis and survival in patients with osteosarcomaImpact of close surgical margin on local recurrence and survival in osteosarcoma.Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Osteosarcoma models: from cell lines to zebrafishOsteosarcoma of jawsFrontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trialAnalysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.Making a case for the socioeconomic determinacy of survival in osteosarcomaIntercalary reconstructions with vascularised fibula and allograft after tumour resection in the lower limb.In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Preventing and Managing Toxicities of High-Dose MethotrexateHER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies.Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma.Diversity of angiogenesis among malignant bone tumors.Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.Telangiectatic osteosarcoma: a review of 87 cases.Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma.Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis.Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: Decoy, trap and kill chTemozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.Expression change of ezrin as a prognostic factor in primary osteosarcoma.Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patientsTreatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy
P2860
Q26797555-D0565E25-7C5D-4A1C-8D7A-A9320E090C2FQ33373879-7B4BB5ED-16B7-453C-A4E0-AFDE7D5EC3CDQ33393253-8F150E27-6A43-4A87-8F64-91A2B6819DF7Q33418020-2CEC9454-31E7-4223-A54E-58793E2F2CF3Q33567522-789DAF48-2231-42F5-BD09-467FDF4E212CQ34538204-8EA5D115-1B5C-4240-B30A-D2BB0761430AQ34636631-1925908B-1EBE-4C2B-8488-8D768EADFE9BQ34797092-DAAC518A-6556-42B4-835E-8D71399D0A08Q34970994-E06C07D5-1465-44E0-8FBA-83256B042760Q35051665-FEB11328-0DB8-404D-A478-591ACBD3F745Q35335157-D6DDFDBE-8DD6-4CA7-BBEA-CF355E8A81C5Q35574435-19D9A120-465E-4B6E-929E-2C359F5A69A1Q35653070-9B5C0BE4-0130-4387-95B8-EDD07AE94745Q35848126-636DAA7F-42BF-4B98-A3A8-A75C65569760Q35897787-0566B3E6-4626-4EFB-82D0-9DA6B9E32C4EQ36181176-DBF93486-5135-4F92-B32B-8C83751D1395Q36503647-2FD917D2-971F-4B8A-90E6-855AD4BEE2FBQ36556924-3A093FB6-8C31-45F5-8A2C-DEDC8A7EE05FQ36585847-6DDD66F9-C038-438C-BF72-E3A1B841B0B7Q36914106-2C8B993D-2D61-4638-8786-C03C2CC8E593Q37106823-32C63C2B-BAB5-474C-8726-65B8C5076EABQ37109503-E2400CB0-A380-4A90-9A13-B7D38F370E39Q37496637-E7ED2EEE-66B3-42AC-B0B2-D15649471BABQ37650306-5455AF1C-2B94-4A87-9AC0-E3B4F1A52F6CQ37688659-07356A04-0307-4F50-B7A7-3247D0B9A510Q38292264-663B3423-BAF5-4177-B06A-0007B200FD7CQ38588532-0D8C3762-461C-42BA-B162-DE74EBB7502AQ38689748-076C6A34-59CD-455D-8E1E-E7943A6CA128Q38911783-3C78E889-78A6-440B-8C5D-9E52DD82CB58Q39229373-683F3EF1-D871-4487-B2D4-54F1BBA63C91Q39419807-AF2BF830-4A92-4495-951F-50D8B7287D28Q40273594-F30858DF-F6A8-4D68-9478-8D5500E70251Q42139483-43581045-5C9C-412F-B81D-69F86846DA54Q44582217-A99EA297-7686-4795-87D0-13E8F1724212Q48156221-03FE2C73-E440-49FC-80C0-301C582503D3Q50328960-D359E3C8-111A-44EF-94E5-04CB41B6317FQ54410065-2EC12233-1D23-47AA-A17A-B0F6D8BA920FQ56996677-47A404B1-5F66-4894-B7BD-D51243870415Q57000564-9AF4F5A5-258A-483A-9C2A-21CE90D944A8
P2860
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@ast
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@en
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@nl
type
label
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@ast
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@en
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@nl
prefLabel
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@ast
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@en
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@nl
P2093
P1476
Neoadjuvant chemotherapy for o ...... of the Rizzoli's 4th protocol.
@en
P2093
Briccoli A
DePaolis M
P304
P356
10.1016/S0959-8049(01)00229-5
P577
2001-11-01T00:00:00Z